NCT00650338

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

A Randomized, Double-masked, Placebo- and Active- Controlled, Parallel-group, Multi-center, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 165 (estimated)
• Sponsor: Santen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	DE-104 ophthalmic solution, low concentration	Topical ocular application
DRUG	DE-104 ophthalmic solution, medium concentration	Topical ocular application
DRUG	DE-104 ophthalmic solution, high concentration	Topical ocular application
DRUG	Placebo	placebo
DRUG	0.005% latanoprost	Topical ocular application

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-09-01
• Completion: 2008-10-01
• First posted: 2008-04-01
• Last updated: 2011-11-03

Locations

14 sites across 1 country: United States